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The V protein of the Paramyxovirus simian virus 5 (SV5) is a multifunctional protein containing an N-terminal 164 residue
domain that is shared with the P protein and a distinct C-terminal domain that is cysteine-rich and which is highly conserved
among Paramyxoviruses. We report the recovery from Vero cells [interferon (IFN) nonproducing cells] of a recombinant SV5
(rSV5) that lacks the V protein C-terminal specific domain (rSV5VC). In Vero cells rSV5VC forms large plaques and grows
at a rate and titer similar to those of rSV5. In BHK or CV-1 cells rSV5VC forms small plaques and grows poorly. However,
even when grown in Vero cells rSV5VC reverts to pseudo-wild-type virus in four to five passages, indicating the importance
of the V protein for successful replication of SV5. Whereas rSV5 grows in many cell types with minimal cytopathic effect
(CPE), rSV5VC causes extensive CPE in the same cell types. To overcome the antiviral state induced by IFN, many viruses
have evolved mechanisms to counteract the effects of IFN by blocking the production of IFN and abrogating IFN signaling.
Whereas rSV5 blocks IFN signaling by mediating the degradation of STAT1, rSV5VC does not cause the degradation of
STAT1 and IFN signaling occurs through formation of the ISGF3 transcription complex. Furthermore, we find that rSV5
infection of cells prevents production of IFN-. The transcription factor IRF-3 which is required for transcription of the IFN-
gene is not translocated from the cytoplasm to the nucleus in rSV5-infected cells. In contrast, in rSV5VC-infected cells IRF-3
is localized predominantly in the nucleus and IFN- is produced. By using ectopic expression of IRF-3, it was shown that after
dsRNA treatment and expression of the V protein IRF-3 remained in the cytoplasm, whereas after dsRNA treatment and
expression of the P protein (which lacks the C-terminal cysteine-rich domain) IRF-3 was localized predominantly in the
nucleus. Thus, SV5 blocks two distinct pathways of the innate immune response, both of which require the presence of theINTRODUCTION
The Paramyxoviridae family of nonsegmented nega-
tive-sense RNA viruses contains many important estab-
lished and emerging human and animal pathogens, in-
cluding Sendai virus, human parainfluenza viruses I–IV,
mumps virus, Newcastle disease virus, measles virus,
rinderpest virus, and the members of the recently clas-
sified Henipavirus genus, the newly identified Nipah and
Hendra viruses. Members of this family are enveloped
viruses with a nonsegmented, single-stranded, negative-
sense RNA genome of 15–16,000 nucleotides. Within
the Paramyxoviridae simian parainfluenza virus 5 (SV5) is
a prototype of the Rubulavirus genus. The SV5 genome
contains 15,246 nucleotides encoding eight proteins
1 Present address: Dept. of Veterinary Science, Pennsylvania State
University, University Park, PA 16802.
2 To whom correspondence and reprint requests should be ad-from seven genes (reviewed in Lamb and Kolakofsky,
2001). SV5, similar to all Paramyxoviruses, consists of a
core of genomic RNA encapsidated by nucleocapsid
(NP) protein to which is bound an RNA polymerase
complex composed of large (L) protein and phosphopro-
tein (P). This core is surrounded by a lipid envelope that
is coated with matrix (M) protein on its inner surface and
penetrated by spike glycoproteins that function for at-
tachment (hemagglutinin-neuraminidase) (HN) and fu-
sion (F). Minor structural components of SV5 include the
SH integral membrane protein (He et al., 1998; Hiebert et
al., 1985, 1988), which plays a role in blocking apoptosis
in infected cells (He et al., 2001) and the V protein
(discussed below).
The V and P proteins (Paterson et al., 1984; Peluso et
al., 1977) are both transcribed from the V/P gene by a
process formally termed pseudotemplated addition of
nucleotides and popularly dubbed “RNA editing” (Pater-
son et al., 1989; Thomas et al., 1988; Vidal et al., 1990).C-terminal specific cysteine-rich domain of the multifunctio
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whereas the P mRNA contains two nontemplated G res-
idues which are added cotranscriptionally by the viral
RNA polymerase, presumably by a stuttering mechanism
(Thomas et al., 1988; Vidal et al., 1990; reviewed in Lamb
and Kolakofsky, 2001). The consequence of the addition
of two G residues to create the P mRNA is that the
translational reading frame is changed relative to the V
protein after the editing site. SV5 V and P proteins share
an N-terminal domain of 164 amino acids but have
unique C-terminal domains (Thomas et al., 1988). The
process of pseudotemplated transcription at a specific
site in the V/P gene occurs for almost all members of the
subfamily Paramyxovirinae (reviewed in Lamb and Kola-
kofsky, 2001). However, whereas for the Rubulaviruses
the V mRNA is transcribed directly from the genome
RNA, for the Respiroviruses and the Morbilliviruses the P
mRNA is transcribed directly from the genome RNA and
the V mRNA contains the additional pseudotemplated G
nucleotide(s) (reviewed in Jacques and Kolakofsky, 1991).
The sequence of the unique C-terminal domain of the
V proteins is highly conserved among the paramyxovi-
ruses. This domain, containing seven cysteine residues,
is analogous to but different from classic zinc finger and
RING finger domains (Thomas et al., 1988; reviewed in
Borden, 2000; Klug and Rhodes, 1987; Klug and
Schwabe, 1995). Nonetheless, the measles virus, SV5,
Newcastle disease virus, and Sendai virus V proteins
bind zinc ions (Huang et al., 2000; Liston and Briedis,
1994; Paterson et al., 1995; Steward et al., 1995). The SV5
V protein is incorporated into virions (350 molecules
per virion) and is found associated with the nucleocapsid
(Paterson et al., 1995). For Sendai virus and measles
virus, however, the V protein does not appear to be
incorporated into virions. Recombinant Sendai virus,
measles virus, and rinderpest virus unable to synthesize
the V protein [V() viruses] have been recovered from
cloned DNA, indicating the V protein is not essential for
these paramyxoviruses for replication in tissue culture
(Baron and Barrett, 2000; Delenda et al., 1997; Kato et al.,
1997a; Schneider et al., 1997), although the V proteins
appear to be important for pathogenicity of these viruses
in animals (Baron and Barrett, 2000; Kato et al., 1997a,b;
Tober et al., 1998). Sendai virus deficient in V protein
shows increased antigenome synthesis and transcrip-
tion (Kato et al., 1997a) and expression of the V protein
decreased replication in a defective interfering (DI) RNA
replication assay, indicating that the V protein may neg-
atively regulate viral replication (Curran et al., 1991).
Rinderpest virus unable to synthesis V protein shows an
increase in synthesis of genome and antigenome RNAs.
For the Rubulaviruses, whose V proteins are of a mass
considerably less than those of the Respirovirus or Mor-
billivirus genera, a recombinant virus lacking the V pro-
tein has not been reported.
Although a role for the SV5 V protein in regulating RNA
replication has not been shown, the SV5 V protein is
known to have many functions. It has been shown to
interact with soluble viral NP (Randall and Bermingham,
1996) and the shared N-terminal domain of V and P binds
single-stranded RNA through a basic region (Lin et al.,
1997). The SV5 V protein interacts with a cellular protein
(DDB1), the 127-kDa subunit of the damage-specific
DNA-binding protein (DDB) and this interaction requires
the presence of the V protein-specific C-terminal domain
(Lin et al., 1998a). Expression of the SV5 V protein, via its
C-terminal domain, also acts to slow the cell cycle (Lin
and Lamb, 2000). V protein binding to DDB1 and the
effect of V protein on the cell cycle may be related as
DDB has also been found to interact with CUL-4A (Shi-
yanov et al., 1999), a member of the cullin family of E3
ubiquitin ligases. Although the function of CUL-4A is not
known, the related CUL-1 and CUL-3 proteins are in-
volved in the ubiquitin-mediated degradation of cyclin E
(reviewed in Winston et al., 1999) and cyclin D and p21CIP
(Yu et al., 1998). Interestingly, the changes in the cell
cycle caused by expression of V protein can be partially
reversed by coexpression of DDB1 (Lin and Lamb, 2000).
Last, the SV5 V protein interferes with establishment of
the antiviral state induced by interferons, as discussed
below.
Interferons (IFNs) are the primary innate antiviral cy-
tokines produced in virus-infected cells (reviewed in Bi-
ron and Sen, 2001; Darnell, 1997; Stark et al., 1998).
Induction of IFN- is not fully understood but it is thought
to involve signaling by dsRNA formed in virus-infected
cells leading to the formation of a large transcription
complex which contains among many factors NF-B,
members of the interferon regulatory factor (IRF) family,
including IRF-1, IRF-3, and IRF-7 ATF-2 homodimers or
ATF-2/c-Jun heterodimers (reviewed in Taniguchi et al.,
2001; see also accompanying article, Poole et al., 2002).
Both type I (IFN-/) and type II (IFN-) IFNs can induce
an antiviral state. IFN signaling is initiated when IFN
binds to its receptor on the cell surface, which leads to
phosphorylation of cytoplasmic STAT proteins to produce
DNA-binding complexes that become translocated into
the nucleus. IFN-/ responses are regulated primarily
through the activated transcription complex, ISGF3, that
is composed of a heterodimer of STAT1 and STAT2 in
association with a DNA-binding subunit p48 (IRF-9).
ISGF3 binds to a DNA element, ISRE, found in the pro-
moter of IFN-/-inducible genes. IFN- responses are
mediated via a transcription complex consisting of STAT1
homodimers. The STAT1 homodimer binds to a DNA
element, GAS, found in the promoter of IFN- inducible
genes.
To overcome the antiviral state induced by interferon,
many viruses have evolved mechanisms to counteract
the effects of IFN by blocking the production of IFN and
abrogating IFN signaling (reviewed in Biron and Sen,
2001; Goodbourn et al., 2000). For the paramyxovirus
Sendai virus a block in IFN signaling occurs (Didcock et
al., 1999a; Young et al., 2000) through the viral C protein
leading, directly or indirectly, to inactivation of STAT1
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(Garcin et al., 1999; Takeuchi et al., 2001). The Rubulavi-
ruses, SV5, mumps virus, and hPIV2 all interfere with
IFN-induced antiviral responses by targeting STAT1 (SV5
and mumps virus) or STAT2 (hPIV2) proteins for protea-
somal degradation (Didcock et al., 1999b; Kubota et al.,
2001; Parisien et al., 2001, 2002a,b). For SV5, mumps
virus, and hPIV2, the degradation of STAT1 or STAT2 is
mediated by the V protein (Andrejeva et al., 2002b; Did-
cock et al., 1999b; Kubota et al., 2001; Parisien et al.,
2001). Hence the multifunctional V protein has yet an-
other role in the paramyxovirus lifecycle. For SV5-in-
duced STAT1 degradation and hPIV2-induced STAT2
degradation, the targeting complex minimally requires
expression of V, STAT1, and STAT2 (Parisien et al., 2002b).
The ability of SV5 to induce degradation of STAT1 and
interfere with IFN signaling is species specific and this
finding may in part explain species tropism. Degradation
of STAT1 occurs in SV5-infected primate cells but is
greatly reduced in SV5-infected murine cells (Didcock et
al., 1999a). However, ectopic expression of human STAT2
in mouse cells overcomes the species-specific block
and SV5 virus infection now antagonizes the mouse IFN
signaling pathway by causing degradation of mouse
STAT1 (Parisien et al., 2002a). It is known that sequence
differences in the 164 residue N-terminal shared V/P
domain of SV5 have an important effect on IFN signaling
and the degradation of STAT1 (Chatziandreou et al., 2002;
Young et al., 2001). However, the V protein-specific C-
terminal domain is also involved in targeting STAT1 for
degradation: for mumps virus and hPIV2, expression of
the V protein containing a deletion of the C-terminal
specific domain greatly decreases the affect of V on
STAT1 signaling (Kubota et al., 2001; Nishio et al., 2001).
Although the mechanism by which the SV5 V protein
mediates the proteasomal degradation of STAT 1 is not
known, it seems possible it could involve the association
of V protein with DDB1 and the E3 ubiquitin ligase pro-
tein cullin 4A.
Here we report recovery of a recombinant SV5 (rSV5)
that lacks the V protein C-terminal specific domain (VC)
and we describe properties of the rSV5VC virus includ-
ing its inability to mediate STAT1 degradation and con-
comitantly its inability to defeat STAT 1 signaling. Fur-
thermore, we also show that whereas wt SV5 infection
prevents production of IFN-, rSV5VC infection permits
production of IFN-. We find that the transcription factor
IRF-3 is not transported from the cytoplasm to the nu-
cleus in wt SV5-infected cells but in rSV5VC-infected
cells IRF-3 is localized predominantly to the nucleus. It
was found that the V protein, but not the P protein,
directly or indirectly causes IRF-3 to remain cytoplasmi-
cally localized after dsRNA stimulation. Thus, SV5 blocks
two distinct pathways of the innate immune response,
both of which require the presence of the C-terminal-
specific domain of the multifunctional SV5 V protein.
RESULTS
Recovery of rSV5 containing a deletion of the
C-terminal domain of the V protein
To study the role of the V protein in the SV5 lifecycle,
many attempts were made to generate a recombinant
virus that would express only the P mRNA and not the V
mRNA (due to mutation of the RNA editing site—for
experimental approach used, see Delenda et al., 1997).
Even though the genome length was maintained as a
multiple of six nucleotides (Calain and Roux, 1993), all
attempts over 3 years to recover a virus that could not
express the V protein failed, even when the V protein
was expressed in trans from an expression plasmid
during the initial transfection. It has been shown previ-
ously that the V protein C-terminal unique domain is
involved in several functions of the V protein (cell-cycle
regulation, DDB1 interactions, STAT1 degradation). Thus
we attempted to recover a virus containing a V protein in
which the C-terminal unique domain was deleted. Two
translational stop codons were introduced into the V
reading frame, one after residue 169 and one at the
equivalent of V residue 172. Neither mutation changed
the amino acid sequence of the P protein. We used a
modification (Waning et al., 2002) of the SV5 reverse
genetics system (He et al., 1997) that improved the ease
of recovery of rSV5 from cloned DNA. Rather than infect-
ing cells with vaccinia virus-expressing bacteriophage
T7 RNA polymerase, the cell-line BSR T7/5 (Buchholz et
al., 1999), which stably expresses T7 RNA polymerase,
was used. The wt and mutant infectious SV5 cDNA
plasmids were cotransfected together with expression
plasmids encoding the viral proteins NP, P, and L into
BSR T7/5 cells such that SV5 ()-strand antigenome
RNA and mRNAs for NP, P, and L were transcribed. The
cDNA genome construct encoding VC gave rise to
recombinant virus (rSV5VC) after passage from the BSR
T7/5 cells onto Vero cells in the first attempt. Vero cells
were selected for amplification of the virus stock be-
cause Vero cells do not produce interferon and we con-
sidered it likely that an altered V protein may have al-
tered properties with respect to its effect on IFN signal-
ing. We were unable to demonstrate that defects
observed with rSV5VC could be complemented by V
protein expressed in transfection/infection experiments
due to extensive cytopathic effects (see Fig. 5).
Confirmation of the engineered mutations in the
rSV5VC stocks was obtained by nucleotide sequencing
of RT-PCR products derived from vRNA (Fig. 1). All of the
recovered viruses contained a tyrosine codon at V resi-
due 166 due to the deliberate introduction of a restriction
endonuclease site in the V/P gene to facilitate the pro-
duction of the mutant. However, after four to five pas-
sages in Vero cells and plaque purification, rSV5VC
virus was found to revert to a pseudo-wild-type with both
stop codons being altered. The natural residues in the P
protein G170 and I172 were unchanged but new residues
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were introduced into the VC protein, Q170 and R172.
Interestingly, R172 is conserved among all V proteins of
Paramyxoviruses (Lamb and Kolakofsky, 2001; Tidona et
al., 1999). In the RT-PCR sequencing sample shown (Fig.
1) a sporadic mutation (I156) in the revertant virus was
also identified but this was not found in another revertant
virus stock. Thus, the rapid accumulation of revertant
virus suggests that deletion of the C-terminal unique
domain of V protein is deleterious to the multiplication of
SV5 and there is a strong selective pressure for the
recovery of pseudo-wt virus.
To confirm that the rSV5VC virus did not express an
intact V protein, immunofluorescent staining was per-
formed by using an mAb 31C6 specific for the V protein
C-terminal unique domain. In rSV5VC-infected cells no
specific V staining was observed but in rSV5-infected
cells V staining was readily detected in the cytoplasm of
cells (Fig. 2). Staining for the surface glycoprotein HN is
shown for comparison. Fewer cells were present on the
coverslips at 24–36 h p.i. for rSV5VC-infected cells than
rSV5-infected cells due to cytopathic effects (CPE) (see
below). As is shown below (Fig. 8D) V protein is found
localized predominantly in the nucleus in transfected
FIG. 1. Recovery of rSV5VC and rSV5VC revertant virus. (Top) RT-PCR sequencing of vRNA from rSV5VC (VC) and rSV5VC revertant (VC rev)
virus-infected Vero cells. Mutated nucleotides and residues are indicated. (Bottom) Partial coding sequences of V protein and P protein. Nucleotide and
codon changes are highlighted. Underline sequence confers a restriction enzyme site to facilitate construction of the parental genome plasmid.
FIG. 2. Immunofluorescent staining patterns of rSV5- and rSV5VC-in-
fected cells. CV-1 cells on glass coverslips were infected with rSV5 or
rSV5VC and at 24 h p.i. The cells were fixed with 1% formaldehyde and
permeabilized with 0.1% saponin. Cells were stained with an mAb specific for
the C-terminal unique domain of V protein (31C6) (Paterson et al., 1995) or
rabbit polyclonal sera specific for HNand FITC-conjugated goat anti-mouse or
Texas red conjugated goat anti-rabbit secondary antibody. Fluorescence was
examined using a Zeiss 410 confocal microscope and appropriate filter sets.
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cells and in virus-infected cells when stained using an
N-terminal-specific mAb (Pk). A possible explanation
for this apparent discrepancy is the C-terminal-spe-
cific mAb does not detect V protein that is localized to
the nucleus (data not shown), most likely because the
V protein is complexed via its C-terminal domain with
the cellular protein DDB1. In virus-infected cells a
greater amount of V protein is expressed and the V
protein localized in the cytoplasm is detected by the
C-terminal-specific mAb.
Analysis of the viral proteins synthesized in Vero
and HeLa T4 cells infected with rSV5 and rSV5VC
showed the expression of V protein in rSV5-infected
cells and the expression of the faster mobility VC
protein in rSV5VC-infected cells (Fig. 3). The relative
expression levels of the viral polypeptides examined
(NP, P, M, F) for rSV5 and rSV5VC appeared to be
similar. A polypeptide species of a similar, but not
identical, mobility to the V protein was observed in
rSV5VC-infected cells (asterisk, Fig. 3) and this spe-
cies is known to be a degradation product of the P
protein (Thomas et al., 1988). Immunoprecipitation us-
ing an antibody specific for the C-terminal of the V
protein did not detect a V-specific protein in rSV5VC-
infected cells (Fig. 3). A pulse-label chase protocol in
HeLa cells indicated that the VC protein is relatively
unstable (t1/2  45 min) (data not shown).
rSV5VC plaque size in BHK cells and Vero cells and
growth curve in Vero cells
Plaque assay of rSV5 and rSV5VC in BHK cells (the
conventional cell line used for plaquing SV5) indicated
that SV5VC formed only pinpoint plaques in compar-
ison to the irregularly sized plaques of rSV5 virus (Fig.
4A). A growth curve of rSV5VC in BHK cells indicated
that the virus grew to 2 logs lower titer than rSV5
(data not shown). In contrast to the plaques formed in
BHK cells, in Vero cells rSV5VC formed discrete
plaques with sharply defined edges that were more
regular in shape and slightly larger than rSV5 plaques
formed in Vero cells (Fig. 4B). The precise number of
plaques between the two viruses and BHK cells and
Vero cells cannot be compared as the data shown
were derived from different experiments. A single-step
growth curve of rSV5 and SV5VC in Vero cells indi-
cated that the two viruses had similar growth rates
and maximum titers, despite the differences in plaque
size (Fig. 4B).
rSV5VC infection causes extensive CPE in many cell
types
The cytopathic effect caused by SV5 in virus-in-
fected cells ranges from very little in MDCK cells
(Choppin, 1964) to massive syncytia formation in BHK
cells (Holmes and Choppin, 1966). Recently we ob-
FIG. 3. Protein expression in rSV5- and rSV5VC-infected cells. Mock-, rSV5-, and rSV5VC-infected Vero cells (A) and HeLa T4 cells (B) were
metabolically labeled with 100 Ci/ml 35S-Promix for 2 h at times p.i. indicated. Polypeptides were immunoprecipitated using antibodies as follows:
anti-V/P  mAb Pk; anti-NP  mAb NPd, anti-V  mAb clone 31C6; anti-NP, V/P, M, F  mixture of mAbs and polyclonal sera specific for NP, V/P,
M, and F. The polypeptide band indicated by an asterisk is a fragment of P that closely migrates with V (Thomas et al., 1988).
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served for a recombinant SV5 lacking the SH gene that
this virus (rSV5SH), unlike wt virus, caused apoptosis
in MDCK cells (He et al., 2001). We observed that
rSV5VC infection of several cell types, e.g., HeLa,
CV1 cells, Vero cells, and L929 cells, showed a severe
CPE by 30 h p.i. Whereas for rSV5 infection of HeLa
cells produced small foci of syncytia could be ob-
served from 24 h p.i. onward, rSV5VC-infected cells
at times  30 h p.i were detaching from the monolayer
(Fig. 5). Data from propidium iodide staining analysis
of cell DNA and from TUNEL assays suggested that
the CPE was due to increased apoptotic cell popula-
tions in the rSV5VC-infected cells by 30 h p.i.,
whereas an apoptotic cell population was not detected
in rSV5-infected HeLa cells (data not shown). Although
CPE induced by rSV5VC in Vero and HeLa cells was
evident by 30 h p.i, protein synthesis did not appear to
be greatly decreased at this time (Fig. 3) nor was virus
particle production (Fig. 4B). The formation of large
discrete plaques in Vero cells by rSV5VC may be due
to the induction of apoptosis.
rSV5VC infection does not cause degradation of
STAT1 and does not block IFN signaling
To examine whether the V protein C-terminal do-
main was required for the degradation of STAT 1,
lysates of mock, rSV5-, and rSV5VC-infected cells
were prepared and an immunoblot for STAT 1 per-
formed. As shown in Fig. 6A, whereas in rSV5-infected
cells STAT 1 levels were very low, in rSV5VC-infected
cells STAT 1 levels at 18 h p.i. were comparable to
mock-treated cells and by 36 h p.i. were greater than
mock-treated cells. Consistent with this observation,
in a test for the presence of STAT 1 by measuring IFN
signaling using a luciferase reporter assay in Vero
cells infected with rSV5 or rSV5VC, it was found that
whereas rSV5 largely abolished IFN signaling,
rSV5VC infection of cells induced a strong IFN sig-
naling response on treatment of cells with IFN- that
at 10 h p.i. was greater than in mock-treated cells (Fig.
6B). We did not examine times later in the infection
cycle due to the increased CPE in the rSV5VC-in-
fected cells. To examine further the differential effect
of rSV5 and rSV5VC infection on IFN signaling, the
assembly of the IFN responsive transcription complex
ISGF3 was examined using an electrophoretic mobility
shift assay (EMSA) with an oligonucleotide containing
an ISGF3 promoter sequence. As shown in Fig. 6C a
shift of labeled probe corresponding to binding of the
assembled ISGF3 complex was only observed in
rSV5VC-infected cell lysates and not in rSV5-infected
cell lysates. Note that the IFN signaling experiment
(Fig. 6B) was performed in Vero cells which are
IFN-nonproducers and thus IFN was added to the
cells to observe signaling on rSV5VC infection,
whereas in the EMSA assay (Fig. 6C) 2fTGH cells (IFN
producers) were used and ISGF3 formation occurred
in SV5VC-infected cells in the absence of addition of
exogenous IFN.
SV5 infection but not rSV5VC infection inhibits IFN-
production
The observation that the extent of IFN signaling and
ISGF3 complex formation was greater in rSV5VC-
infected cells than in mock-infected cells suggested
that this stimulation might be due to the production of
IFN. To examine further the effect of SV5 infection on
IFN production, the amount of IFN- released into the
media of SV5- and rSV5VC-infected HeLa cells was
measured using an ELISA assay. As shown in Fig. 7,
very little IFN- was detected from SV5-infected cells
but by 36 h p.i. large amounts of IFN- were detected
from rSV5VC-infected cells. Thus, these data suggest
that the SV5 V protein is involved in preventing IFN-
production in infected cells.
FIG. 4. Plaque sizes and single-step growth curves of rSV5 and
rSV5VC. (A) Plaques of rSV5 and rSV5VC on BHK 21-F cells or Vero
cells stained with Giemsa. (B) Vero cells were infected at an m.o.i. of 10
PFU/cell with rSV5 or rSV5VC and the media harvested at 1-day
intervals up to 5 days p.i. The virus titers were determined by plaque
assay on BHK cells.
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SV5 V protein blocks the nuclear localization of
interferon regulatory factor 3 (IRF-3) on dsRNA
stimulation
The transcription factor IRF-3 has been shown to be
important for the transcription of the IFN- gene (Sato et
al., 1998; Schafer et al., 1998; Weaver et al., 1998; Yon-
eyama et al., 1998). Upon virus infection or exposure to
dsRNA, IRF-3 which is constitutively expressed and cy-
toplasmically localized is phosphorylated on C-terminal
serine and threonine residues (Lin et al., 1998b). This
activation by phosphorylation results in the relocalization
of IRF-3 from the cytoplasm to the nucleus and the
induction of transcription of host defense genes (Juang
et al., 1998; Sato et al., 1998; Wathelet et al., 1998; re-
viewed in Reich, 2002). Several viruses have evolved a
means of interfering with IRF-3 functions and hence
down-regulating the production of IFN. The E6 protein of
human papillomavirus binds to IRF-3, inhibiting the tran-
scriptional activation of the IFN- gene (Ronco et al.,
1998) and expression of the influenza virus NS1 protein
leads to a block in phosphorylation of IRF-3 and a cyto-
plasmic localization of IRF-3 in the presence of known
inducers of IFN (Talon et al., 2000). Thus, because SV5
infection prevents the production of IFN-, we examined
the subcellular localization of IRF-3 on expression of V
protein in rSV5- and rSV5VC-infected cells.
To examine the localization of endogenous hIRF-3 in
HeLa cells infected with rSV5 and rSV5VC, cells were
stained with an mAb (SL-12) specific for hIRF-3 (Ronco et
al., 1998) and the cytoplasmic vs nuclear distribution of
IRF-3 staining was examined by fluorescence micros-
copy for 400 randomly chosen cells (see Fig. 8A, for
example). It was observed that whereas in rSV5-infected
cells hIRF-3 was predominantly localized to the cyto-
plasm (12.0% of cells showed some nuclear staining), in
rSV5VC-infected cells hIRF-3 was predominantly local-
ized to the nucleus (67.7% cells showed strong nuclear
staining).
To examine further the changes in the subcellular
localization of hIRF-3 on SV5 infection, a biologically
active green fluorescent protein (GFP) tagged version of
IRF-3 was used and HeLa-CD4-LTR--gal cells were
transfected, as these cells are highly transfectable. Cells
were infected with rSV5 or rSV5VC and then trans-
fected with the hIRF-3-GFP expression plasmid and flu-
orescence examined by confocal microscopy. In SV5-
infected cells hIRF-3-GFP showed a cytoplasmic local-
ization (Fig. 8B, panels A, D, C, and F), whereas in
rSV5VC-infected cells hIRF-3-GFP showed a largely nu-
clear localization (Fig. 8B, panels G, J, I, and L). We also
observed intensely staining small cytoplasmically local-
ized granules when the bulk of hIRF-3-GFP was localized
to the nucleus but the significance of these observations
is unknown. In rSV5-infected cells and to a lesser extent
FIG. 5. CPE of rSV5 and rSV5VC in HeLa cells. HeLa T4 cells were infected at an m.o.i. of 10 PFU per cell. At varying times p.i. cells were
photographed using a Nikon inverted microscope and a Kodak DCS 420 digital camera.
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in rSV5VC-infected cells inclusion bodies were ob-
served that stained with the Pk mAb specific for the
shared V/P domain as have been observed previously
(Randall and Bermingham, 1996). It was also observed
that some of the hIRF-3-GFP colocalized with these in-
clusion bodies. For reasons we do not know we ob-
served that it was very difficult to obtain 10% transfec-
tion efficiency in SV5-infected cells, whereas transfection
of the cells without virus infection was possible in 85–
90% of the cells. Conversely it was difficult to infect with
SV5 cells that had been transfected with plasmid DNA.
To demonstrate more directly a role of the V protein in the
altered subcellular localization of hIRF-3, we performed
cotransfection experiments. Expression of hIRF-3-GFP, as
expected, was observed to be predominantly cytoplasmic
but on treatment of hIRF-3-GFP-expressing cells with
poly(I)poly(C), to induce IFN production, a large percentage
of the cells exhibited nuclear staining of hIRF-3-GFP (Fig.
8C). In cells treated with poly(I)poly(C) we again observed
some intensely staining cytoplasmic granules. Expression
of the SV5 V protein showed some cytoplasmic localization
but also a strong nuclear staining as observed previously
(Randall and Bermingham, 1996), whereas expression of
the SV5 P protein (which shares 164 residues in common
with V protein before the V protein C-terminal unique do-
main) exhibited a predominantly cytoplasmic staining pat-
tern (Fig. 8C). When hIRF-3-GFP and V protein were coex-
pressed and the cells treated with poly(I)poly(C), V protein
showed a predominantly nuclear localization and hIRF-3-
GFP exhibited a predominantly cytoplasmic localization
(Fig. 8D). In contrast, when hIRF-3-GFP and P protein were
coexpressed, hIRF-3-GFP showed a predominantly nuclear
localization in the majority of the cells. Expression of the P
protein was used as the control for expression of the V
protein in this experiment because VC protein is unstable
and could not be detected by fluorescent staining.
rSV5VC is less pathogenic in STAT1/ mice than wt
SV5
Recently we established a small animal model system
for studying SV5 pathogenesis using 4- to 6-week-old
BALB/c mutant mice homozygous for a targeted disrup-
tion of STAT1 (He et al., 2001). To examine for the repli-
cation of rSV5VC in mouse lungs, wt mice (BALB/c) and
STAT1/ mice were inoculated intranasally with 106 PFU
FIG. 6. The C-terminus of the V protein is required to block IFN
signaling. (A) The C-terminal unique domain of V protein is required for
STAT1 degradation. HeLa cells infected with rSV5 or SV5VC were
lysed 18 and 36 h p.i. Lysates were subjected to SDS–PAGE on 10%
gels and polypeptides transferred to an Immobilon filter and immuno-
blotted using antibodies specific for STAT1. (B) Comparison of the
ability of mock-infected and rSV5 (W3)- and rSV5VC (VC)-infected
cells to block IFN signaling. Cells were transfected with a plasmid that
contained the luciferase gene under the control of an IFN-/-respon-
sive promoter together with plasmid pJATlacZ, in which the lacZ gene
is under the control of the rat -actin promoter. At 6 or 10 h p.i. the
culture medium was supplemented with IFN or left untreated. After a
further 4 h the cells were lysed and luciferase activity was measured
(relative light units) and normalized to -galactosidase activity. (C).
EMSA of IFN-activated transcription factor complex ISGF3. 2fTGH cells
were mock-, rSV5-, or rSV5VC-infected, and at 8 or 16 h p.i. the culture
medium was supplemented with IFN () or left untreated (). After a
further hour nuclear extracts were prepared and analyzed by EMSA
using a probe specific for the 9-27 gene ISRE. The mobility of the
transcription factor complex ISGF3 is indicated.
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rSV5 or rSV5VC (five mice per group). After 4 days the
mice were sacrificed, the lungs were homogenized, and
virus titers determined by plaque assay. As shown in the
insert to Fig. 9, rSV5 and rSV5VC grew to equivalent
titers in lungs of wt BALB/c mice (0.68  104 and 0.66 
104 PFU/ml, respectively). This finding was not unex-
pected as it has been shown previously that rSV5 grows
poorly in mice, likely because the V protein does not
cause degradation of mSTAT1 protein in murine cells
(Chatziandreou et al., 2002; Didcock et al., 1999a; Pa-
risien et al., 2002a; Young et al., 2001). In STAT1/ mice,
rSV5 grew to a titer of 0.44  107 PFU/g of lung, whereas
rSV5VC only grew to a titer of 0.14  106 PFU/g of lung
tissue. The higher titer of rSV5 than rSV5VC in mice that
lack a STAT1 signaling pathway suggests that the unique
C-terminus of the V protein has another function in the
virus lifecycle in addition to mediating the degradation of
STAT1 protein. Examination of the body weight and sur-
vival of mice following inoculation with 106 PFU rSV5 (11
mice per group), rSV5VC (10 mice per group), or mock-
infected mice (8 mice per group) showed that whereas
mice infected with rSV5 lost weight and died by Day 10,
mice infected with rSV5VC lost some weight from Day
4 to 10, typical with mild virus infection, but after Day 10
they regained their weight and gained weight slightly
better than mock-infected mice for the next 10 days.
These data suggest that rSV5VC is less pathogenic in
vivo than wt rSV5, even though it causes vastly greater
CPE in mouse and human cells, a finding consistent with
the notion of virus clearance by apoptosis in infected
cells in an infected animal.
DISCUSSION
The V/P/(C) genes of the Paramyxoviruses encode
proteins that provide a rich diversity of distinct functions
that affect both virus RNA transcription/replication and
response of the host cell to viral infection. The V protein
of the Rubulaviruses is encoded directly by the virus
genome, whereas the V protein of the Respiro-, Morbilli-,
and Henipaviruses results from the RNA editing process
(reviewed in Lamb and Kolakofsky, 2001). However,
whereas the V proteins of Rubulaviruses are small pro-
teins and only contain 230 amino acid residues, the V
proteins of Respiro-, Morbilli-, and Henipaviruses are
larger proteins and contain 300–470 amino acid resi-
dues. Furthermore, the Rubulavirus V/P gene lacks the
open reading frame encoding the C protein(s) found in
Respiro-, Morbilli-, and Henipaviruses. There is a short
stretch of relatedness between a region of Respirovirus
C proteins and a region of Rubulavirus V proteins (Lamb
and Kolakofsky, 2001), and although the significance of
this homology is currently unknown, it is interesting to
note that the C protein of Sendai virus leads to inactiva-
tion of STAT1 (Garcin et al., 1999, 2000; Takeuchi et al.,
2001), whereas the Rubulavirus V proteins target STAT1
or STAT2 for proteasomal degradation (Andrejeva et al.,
2002; Didcock et al., 1999b; Kubota et al., 2001; Parisien
et al., 2001, 2002a,b). Thus, it has been suggested that
the V protein N-terminal domain that is shared with the P
protein has functional differences between the Rubula-
viruses and the Respiro-, Morbilli-, and Henipaviruses
(Lamb and Kolakofsky, 2001). Perhaps fitting with this
conjecture is the fact that there is no report of recovery
FIG. 7. IFN production in rSV5- and rSV5VV-infected cells. HeLa cells were infected with rSV5 or rSV5VV and media samples were taken at
various times p.i. The amount of IFN- was measured using an ELISA. Samples are triplicates. Values shown are average  SEM.
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FIG. 8. Intracellular localization of hIRF-3 in cells treated with poly(IC). (A) Intracellular localization of hIRF-3 in SV5- and rSV5VC-infected cells.
At 40 h p.i. HeLa cells were stained with mAb SL-12 specific for hIRF-3 and goat anti-mouse secondary antibody and fluorescence examined with
a Nikon FXA fluorescent microscope. (B) HeLa-CD4 LTR--gal cells were infected with rSV5 or rSV5VC and transfected with phIRF-3-GFP as
described under Materials and Methods. (A–F) rSV5-infected cells. (G–L) rSV5VC-infected cells. (A, D, G, J) hIRF-GFP fluorescence. (B, E, H, K) mAb
Pk staining for P and V followed by Alexa Fluor 594 conjugated goat anti-mouse antibody (red). (C, F, I, L) Dual fluorescence. The panels in each row
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show the same field of cells. (C) HeLa CD4-LTR--gal cells were transfected with plasmids expressing hIRF-3-GFP, V, or P and prepared for confocal
microscopy as described under Materials and Methods. Cells expressing hIRF-3-GFP, V, or P individually. () Poly(IC) indicates cells treated with
poly(I)poly(C) (25 g/ml 4–24 h p.t.). For hIRF-3  poly(IC) two views of the same field of cells are shown at two focal planes to show different cross
sections through the nuclei. (D) Poly(IC)-treated cells coexpressing hIRF-3-GFP and V or P. In C and D hIRF-3 was detected by the fluorescent signal
of GFP (green) and P and V were detected by staining with mAb Pk followed by Alexa Fluor 594 conjugated goat anti-mouse antibody (red).
Fluorescence in B, C, and D was examined using a Zeiss SLM410 confocal microscope.
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of a V-minus Rubulavirus mutant, whereas infectious
Sendai virus, measles virus, and rinderpest virus that are
V-minus (caused by inactivation of RNA editing site) are
viable viruses in tissue culture (Baron and Barrett, 2000;
Delenda et al., 1998; Kato et al., 1997a; Schneider et al.,
1997). Nonetheless, although these latter V-minus vi-
ruses may be viable in tissue culture, in animal model
systems both V-minus Sendai virus and V-minus measles
virus are attenuated (Kato et al., 1997a; Mrkic et al., 2000;
Patterson et al., 2000; Tober et al., 1998; Valsamakis et
al., 1998), a finding that suggests a luxury function of the
V proteins of these viruses in interacting with the host
organism. Recovery of hPIV2 that lacks the conserved
C-terminal domain of the V protein has been reported
(Kawano et al., 2001). This hPIV2VC virus grew in Vero
cells (IFN nonproducer cells) but would not grow in CV-1
or FL cells unless anti-IFN- antibody was added, sug-
gesting that the hPIV2 V protein C-terminal specific do-
main is related to IFN resistance (Kawano et al., 2001). It
is also known for SV5 and mumps virus, from in vitro
studies, that the V protein C-terminal-specific domain is
required for these proteins to mediate STAT1 degrada-
tion and thus block STAT1 signaling (Kawano et al., 2001;
J. Andrejeva, et al., 2002a).
The recovery of rSV5VC from Vero cells, the forma-
tion by rSV5VC of large plaques in Vero cells, and the
growth of rSV5VC in Vero cells at a similar rate to rSV5,
but the formation only of small plaques by rSV5VC in
BHK or CV-1 cells and the poor growth of rSV5VC in
these latter cell types, is a finding consistent with
rSV5VC failing to interdict interferon production and/or
signaling. However, the observation that it did not prove
possible to recover a recombinant SV5 containing a “V
gene knock-out,” together with the observation that
rSV5VC reverted to pseudo-wt virus on multiple occa-
sions even when rSV5VC was grown in Vero cells,
suggests that either SV5 is imperfect at ablating the
production of and/or response to IFN, or there is another
FIG. 9. Growth of rSV5VC in STAT1/ mice. Six-week-old BALB/c STAT1/ mice were inoculated intranasally with mock or 106 PFU of rSV5 or
rSV5VC as described under Materials and Methods. Weights of the mice were monitored and graphed as a percentage of body weight of the mice
(y-axis) at the date of inoculation. Note that error bars for wt SV5 are smaller than the size of the graph point. (Insert) Titer of rSV5 and rSV5VC in
the lungs of wt BALB/c mice and BALB/c STAT1/ mice.
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essential role of the V protein and its C-terminal domain
in virus replication, e.g., the ability of the V protein to slow
progression of the cell cycle (Lin and Lamb, 2000) or to
affect RNA transcription/replication. Whereas SV5 is well
known for causing minimal CPE in many cell types
(Choppin, 1964), rSV5VC caused extensive CPE in
many cells types and rSV5VC-infected HeLa cells were
apoptotic (data not shown). However, because of the
multiple functions of the V protein in the virus lifecycle, it
is not clear at the present time if the observed CPE can
be attributed to IFN production or signaling. As an in vivo
model system for SV5 infection, 4- to 6-week-old BALB/c
mutant mice homozygous for a targeted disruption of
STAT1 were used (He et al., 2001) and it was found that
rSV5VC was less pathogenic than wt rSV5, even though
it causes vastly greater CPE in mouse and human cells.
However, this finding is consistent with the notion of
clearance of apoptotic cells in a host species.
Infection of HeLa cells with rSV5VC did not result in
a loss of STAT1 protein, as occurs in wt SV5-infected
cells, and there was not a loss of IFN signaling, as
occurs in wt SV5-infected cells. As the extent of IFN
signaling and ISGF3 complex formation in rSV5VC-
infected cells was greater than that found in mock-in-
fected cells, it suggested this stimulation might be due to
the production of IFN. Related to this is an observation
made by Purnell W. Choppin over 30 years ago. He found
that wt SV5 infection of MDCK and HeLa cells resulted in
very low to undetectable levels of production of type I
IFN and that the SV5-infected cells did not respond to
addition of exogenous IFN. He speculated that SV5 had
evolved mechanisms to block IFN production and action
(unpublished observations cited in Choppin and Com-
pans, 1975). As shown in this and in the accompanying
article (Poole et al., 2002), such an effect may indeed be
mediated by the V protein, specifically involving its C-
terminus.
The transcription factor IRF-3 is important for transcrip-
tion of the IFN- gene on virus infection or exposure to
dsRNA. IRF-3 is constitutively expressed and cytoplas-
mically localized and on stimulation is phosphorylated by
an unidentified protein kinase and this phosphorylation
results in the subcellular relocalization of IRF-3 from the
cytoplasm to the nucleus, triggering induction of host
defense genes (reviewed in Reich, 2002). As shown in
the accompanying article infection of cells with wt SV5,
but not with rSV5VC, diminishes dsRNA signaling using
an IFN- promoter reporter assay (Poole et al., 2002). We
show in this article that in SV5-infected cells IRF-3 is
largely cytoplasmically localized, whereas in rSV5VC-
infected cells IRF-3 is largely localized to the nucleus.
Our expression experiments indicate that the V protein
mediates the cytoplasmic localization of IRF-3 upon
dsRNA treatment and the V protein C-terminal domain is
required for this process. These findings correlate with
the finding that mutations in the V protein C-terminus
greatly reduce IFN- induction (Poole et al., 2002). The
mechanism by which expression of the V protein medi-
ates its effect in blocking translocation of IRF-3 into the
nucleus remains to be determined. It is possible that the
V protein interacts directly or indirectly with IRF-3 such
that the activating phosphorylation of IRF-3 is prevented
or that IRF-3 is in a complex such that it is physically
retained in the cytoplasm. However, and perhaps more
likely, the mechanism may affect a factor upstream in the
pathway to IRF-3 activation as NF-B, which is also
required for IFN- transcription and which also requires
activation by phosphorylation, is activated in rSV5VC-
infected cells but is not activated in rSV5(W3)-infected
cells (see also accompanying article, Poole et al., 2002).
Interestingly, in the deletion mapping and mutagenesis
experiments deletion of only the C-terminal domain of
the V protein or mutation of its conserved cysteine res-
idues affected dsRNA signaling using an IFN- promoter
reporter assay (see also accompanying article, Poole et
al., 2002), whereas deletions in the V protein C-terminus
and in a V protein N-terminal region affected STAT1
signaling (Young et al., 2001; Andrejeva et al., 2002a),
suggesting that the two processes are mediated by dis-
tinct processes both of which require the V protein C-
terminal cysteine-rich domain.
The effect of SV5 V protein expression on the cytoplas-
mic localization of IRF-3 is consistent with the means by
which other viruses inhibit the expression of host de-
fense genes such as IFN-. Human papilloma virus 16
(HPIV16) E6 protein binds to IRF-3 leading to a block in
IRF-3 transcriptional activity (Ronco et al., 1998). Influ-
enza A virus NS1 protein binds to dsRNA, preventing
activation of the dsRNA-activated protein kinase, PKR (Lu
et al., 1995). In addition the influenza virus NS1 protein
inhibits the activation of IRF-3, which then fails to enter
the nucleus (Talon et al., 2000). Presumably these effects
of the NS1 protein are not 100% efficient as IFN was
initially discovered in experiments involving heat inacti-
vated influenza virus (Issacs and Lindenmann, 1957). The
influenza virus NS1 protein also inhibits host-cell mRNA
polyadenylation and nonpolyadenylated mRNAs are not
exported from the nucleus (Chen et al., 1999). Perhaps
influenza virus evolved this function of the NS1 protein to
block the antiviral effect of IFN-induced proteins. For the
Paramyxoviruses, in addition to SV5 it has been found
that measles virus (Naniche et al., 2000) and now Sendai
virus and hPIV2 (see also accompanying article, Poole et
al., 2002) interfere with interferon production and al-
though the mechanism by which this occurs has not
been elucidated for Sendai virus and hPIV2, again the V
protein is involved in the process (see also accompany-
ing article, Poole et al., 2002).
The ability of the SV5 V protein to block two distinct
pathways of the innate immune response, IFN- produc-
tion and IFN signaling, is likely to be important in the
pathogenicity and host range of the virus. This raises the
question: how can SV5 V protein accommodate the mul-
tiple protein–protein interactions presumably required
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for its multifunctionality? The conserved sequence of the
V protein C-terminal domain binds two atoms of zinc
(Paterson et al., 1995), and although it is analogous to, it
is different from, classic zinc fingers or RING fingers
(Borden, 2000; Klug and Schwabe, 1995). Nonetheless
the V protein C-terminal domain is likely to have some
defined structure. However, it has been found recently
that the shared N-terminal domain of the measles P and
V proteins is natively unfolded (Karlin et al., 2002), a
property common to the acidic activation domains of
transcription factors that also have to form multiple pro-
tein–protein interactions (Wright and Dyson, 1999). By
using algorithms (Romero et al., 2001) that predict un-
structured regions of proteins, 54 residues (67–120) of
the N-terminal region of SV5 V protein are predicted with
high confidence to be intrinsically unstructured (K. Rat-
cliff and R. A. Lamb, unpublished results). Further bio-
chemical work will be needed to support this hypothesis
but a natively unfolded domain may provide the means of
forming multiple protein–protein interactions.
MATERIALS AND METHODS
Viruses and cells
HeLa T4, CV-1, Vero, 2FTGH, MDCK, and BSR T7/5
(Buchholz et al., 1999) cells were maintained in DMEM
with 10% fetal calf serum (FCS). BHK 21-F cells were
maintained in DMEM with 10% tryptose phosphate broth
and 10% FCS. HeLa CD4-LTR--gal cells were grown and
maintained in DMEM supplemented with 10% fetal bo-
vine serum, 200 g/ml G418 (Genetecin, Invitrogen Inc.,
San Diego, CA) and 100 g/ml hygromycin B (Invitrogen).
These cells were obtained through the AIDS Research
and Reference Reagent Program, Division of AIDS,
NIAID, NIH (HeLa-CD4-LTR--gal from Dr. Michael Emer-
man). All cells used were determined to be free of my-
coplasma contamination by using a PCR-based assay
and specific DNA primers (Boehringer Mannheim, Indi-
anapolis, IN). For virus infection, cell monolayers were
washed with phosphate-buffered saline (PBS) and then
infected with viruses in DMEM-1% BSA at a multiplicity of
infection (m.o.i.) of 0.1 to 10 PFU/cell for 1 to 2 h at 37°C.
The monolayers were then washed and incubated with
DMEM containing 2% fetal calf serum (FCS) at 37°C.
Recovery of mutant rSV5 by reverse genetics
rSV5VC was generated by using a reverse genetics
system from an infectious clone of SV5 (plasmid pBH276)
(He et al., 1997) in which two in-frame tandem stop
codons were made downstream of the RNA editing site
of the V gene (plasmid pBH378) without affecting codons
of the P mRNA (see Fig. 1). BSR T7/5 cells in 3.5-cm-
diameter dishes (60–90% confluent) were transfected
with the genomic cDNA clone for wt SV5 or SV5VC
together with the support plasmids pCAGGS-NP,
pCAGGS-L, and pCAGGS-P using Lipofectamine-PLUS
reagents following the manufacturer’s recommendations
(Invitrogen). Plasmid amounts were as follows: 1.0 g
SV5 genome plasmid, 100 ng pCAGGS-NP, 20 ng
pCAGGS-P, and 500 ng pCAGGS-L. Cells were incubated
with the transfection mix for 12–16 h at 37°C. Cells were
then washed once with PBS and the medium was re-
placed with DMEM supplemented with 2% fetal bovine
serum. Two to four days posttransfection (p.t.) the media
were assayed for the presence of recombinant SV5
(rSV5) by monitoring syncytium formation on BHK-21F
cells. The supernatant fluid from positive dishes was
then used for plaque purification on Vero cells (Paterson
and Lamb, 1993). Virus stocks of rSV5VC were grown in
Vero cells.
Single-step growth rate
Monolayers of Vero cells in 35 mm plates were
washed with PBS and then infected with rSV5 or
rSV5VC in DMEM–1% BSA at an m.o.i. of 10 PFU/cell for
1 to 2 h at 37°C. The cells were then washed with PBS
and maintained in DMEM–2% FCS. Medium was col-
lected at 0, 1, 2, 3, 4 and 5 days p.i. for quantification of
virus by plaque assay on BHK 21F cells.
Reverse transcriptase–PCR amplification and
sequencing
Total RNAs from rSV5VC-infected Vero cells (6-cm-
diameter plates) were purified using an RNeasy kit (Qia-
gen, Chatsworth, CA), according to the manufacturer’s
protocol. Total RNAs were dissolved in 50 l H2O and 19
l was used in a reverse transcriptase (RT) reaction
using appropriate oligonucleotide primers that annealed
to the vRNA () strand. An aliquot of the cDNA was then
amplified in a PCR reaction using appropriate oligonu-
cleotide primer pairs. PCR was carried out at 94°C for 1
min, 55°C for 1 min, and 72°C for 1 min for 40 cycles. The
PCR products were electrophoresed on a 1% agarose gel
and bands were cut out and DNA was purified using a
Qiaex II kit (Qiagen). The purified DNA was then ampli-
fied by PCR using fluorescent dye-labeled chain-termi-
nating nucleotides and the nucleotide sequence was
obtained using the ABI 310 sequencer and ABI Prism
software.
Immunoprecipitation of polypeptides
Vero and HeLa T4 cells were infected with wt rSV5 or
rSV5VC, and at 1 to 2 days p.i. were labeled for 2 h with
35S-Promix label (100 Ci/ml) and the cells lysed in RIPA
buffer and aliquots immunoprecipitated using monoclo-
nal antibody HN4b (Ng et al., 1989; Randall et al., 1987),
anti-F2 synthetic peptide rabbit sera (Dutch et al., 2001),
P-specific mAb 161 (Randall et al., 1987), or anti-V syn-
thetic peptide rabbit sera or V-specific mAb 31C6 (Pater-
son et al., 1995). Polypeptides were analyzed by SDS–
PAGE using 15 or 10% polyacrylamide gels (Paterson and
Lamb, 1993) and radioactivity was analyzed using a Fuji
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BioImager 1000 and MacBas software (Fuji Medical Sys-
tem, Stamford, CT).
IFN signaling and electrophoretic mobility shift
assays
Details of the IFN signaling assay and electro-
phoretic mobility shift assays have been reported else-
where (Didcock, 1999b). Briefly, in EMSA nuclear ex-
tracts were prepared from mock-infected or SV5-in-
fected cells that had or had not been treated with
rHuIFN-A/D for 1 h prior to harvesting at 8 or 16 h p.i.
Protein–DNA complexes were formed by incubating 10
g protein for 15 min at 30°C with 1 ng probe (labeled
with -32P by filling in the GATC 5	 overhangs with
Klenow enzyme on the otherwise double-stranded oli-
gonucleotides 5	 AGGAAATAGAAACTG 3	) in a 20-l
reaction mixture containing 20 mM Tris (pH 8.0), 12%
glycerol, 2 mM MgCl2, 0.6 mM dithiothreitol, and 375
ng poly(dI-dC). Complexes were resolved on 6% native
polyacrylamide (1:30 bisacrylamide/acrylamide) gels
in 0.5 Tris–borate–EDTA, and the dried gels were
visualized by autoradiography.
In the IFN signaling assays, Vero cells were trans-
fected with 1 g DNA and 1.5 l Fugene 6 (Roche)
according to the manufacturer’s instructions. After 24 h,
the cells were infected with SV5 W3 or SV5VC at an
m.o.i. of 5 and induced with 1000 U of rHuIFN-A/D per
milliliter at 6 or 10 h p.i. Cells were lysed 4 h after
induction by IFN. Lysates were prepared and assayed for
luciferase and -galactosidase activity as described pre-
viously (King and Goodbourn, 1994). The relative expres-
sion levels were calculated by dividing the luciferase
values by the -galactosidase values.
Immunoblotting.
HeLa T4 cells in 6-cm plates were infected with
rSV5VC or rSV5. Cells were lysed at 16 and 36 h p.i.
in 0.5 ml of protein lysis buffer (2% SDS, 62.5 mM
Tris–HCl, pH 6.8, 2% dithiothreitol) and lysates were
sonicated briefly to shear DNA. Lysate (80 l) was
subjected to SDS–PAGE using a 10% gel (Paterson et
al., 1984). Polypeptides were transferred to Immo-
bilon-P membrane (Millipore Corp., Bedford, MA) us-
ing a wet-gel transfer apparatus (Bio-Rad, Hercules,
CA). The membrane was first incubated with primary
antibodies against STAT1 (a mixture of A-2, C-136, and
E-23; Santa Cruz Biotechnology, Inc., Santa Cruz, CA)
and then a mixture of anti-mouse and anti-rabbit sec-
ondary antibodies conjugated to horseradish peroxi-
dase. The proteins on the membrane were detected
using the ECL kit (Amersham Pharmacia, Piscat-
away, NJ) and chemiluminescence was detected using
a Storm System phosphorImager (Molecular Dynamics
Inc., Sunnyvale, CA).
Fluorescent microscopy on rSV5- and rSV5VC-
infected cells
CV-1 cells were grown on glass coverslips and in-
fected with rSV5 or rSV5VC. At 24 h p.i. cells were
washed with PBS and then fixed in 1% formaldehyde for
15 min at room temperature. In all further steps, 0.1%
saponin was included in the PBS to permeabilize cells.
The cells were washed with PBS/saponin solution and
incubated for 30 min in a 1:500 dilution of rabbit anti-HN
and mAb 31C6 specific for the C-terminus of the V pro-
tein. Cells were washed extensively in PBS/saponin and
the appropriate secondary antibody [FITC-labeled goat
anti-mouse IgG or Texas red labeled goat anti-rabbit IgG
(Jackson Laboratory, Bar Harbor, ME)] was added to the
cells for 30 min, and the cells were washed in PBS/
saponin. Fluorescent staining was visualized using a
Zeiss LSM 410 confocal microscope (Zeiss, Inc., Thorn-
wood, NY).
Intracellular localization of hIRF-3
Endogenous hIRF-3 was examined by immunofluores-
cent staining of HeLa cells and mAb SL-12 (Ronco et al.,
1998). For hIRF-3-GFP localization, HeLa-CD4-LTR--gal
cells seeded on coverslips in six-well dishes were trans-
fected with 800 ng DNA consisting of 400 ng pCAGGS/P,
400 ng phIRF-3-GFP (Kumar et al., 2000), or 40 ng
pCAGGS/V either alone or in combination with the bal-
ance of the DNA made up of pCAGGS. Transfections
were carried out using Lipofectamine-Plus (Invitrogen)
according to the manufacturer’s instructions. At 4 h p.t.
poly(I)poly(C) [poly(IC)] (Amersham Pharmacia Biotech
Inc.) was added to a final concentration of 25 g/ml and
cells were examined by confocal microscopy at 24 h p.t.
For virus-infection/transfection experiments HeLa-CD4-
LTR--gal cells prepared as described for cotransfec-
tions were infected with either rSV5 virus or rSV5VC
virus or were mock infected. At 1.5 h p.i. the cells were
washed with PBS and transfected with 1 g phIRF-3-GFP
per well using ExGen 500 (Fermentas, Hanover, MD)
according to the manufacturer’s instructions. Infected/
transfected cells were examined by confocal microscopy
24 h p.t. For fluorescence microscopy cells were fixed
and permeabilized by incubating in 2.5% formaldehyde,
0.5% Triton X-100 for 20 min at room temperature and
subsequently incubated with mAb Pk (specific for the
SV5 P and V proteins) (Randall et al., 1987) followed by
Alexa Fluor 594 conjugated goat anti-mouse IgG (HL)
secondary antibody (Molecular Probes, Eugene, OR).
hIRF-3-GFP was detected by GFP fluorescence. Fluores-
cence was visualized using either a Nikon FXA micro-
scope (Fig. 8A) or a Zeiss LSM 410 confocal microscope.
Measurement IFN- in media of virus-infected cells
HeLa cells were infected and media were collected at
different time points postinfection. The amount of IFN-
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was measured using a human IFN- detection kit pur-
chased from PBL Biomedical Laboratories (Piscataway,
NJ) according to the manufacturer’s instruction. The
amount of IFN- was calculated using standard curves
generated from known concentrations of IFN- provided
by the manufacturer.
Animal experiments
Six-week-old BALB/c mice or BALB/c STAT1/ were
first anesthetized and then inoculated intranasally with
50 l PBS containing 106 PFU rSV5 or rSV5VC viruses.
Body weights of the mice were recorded daily thereafter.
Titers of viruses in mouse lungs were determined as
described previously (He et al., 2001).
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